agonistas glp 1 GLP-1 Receptor Agonist Market Growth Analysis GLP-1 Receptor Agonists as Treatments

Clinical trials have shown significant weight loss with Wegovy, often averaging a 15% reduction over 68 weeks

Early medications that simply boosted natural incretin levels had limited effectiveness because the hormones still degraded quickly

The actual level of tax incurred by the Fund may vary and will be dependent on the Funds actual level of earnings and investment and transacting profile

The most commonly prescribed GLP-1 RAs are: Semaglutide: Ozempic (type 2 diabetes), Wegovy (weight loss) Tirzepatide: Mounjaro (type 2 diabetes), Zepbound (weight loss) Dulaglutide: Trulicity (type 2 diabetes) Liraglutide: Victoza (type 2 diabetes), Saxenda (weight loss) According to the Endocrine Society, GLP-1 RAs promote early satiety, reduce food intake, and are associated with weight loss ( Endocr Pract , 2022)